Bottom line
FTXH vs RYHIX: the short answer
FTXH (First Trust Nasdaq Pharmaceuticals ETF) and RYHIX (Health Care Fund) share a meaningful slice of their top holdings — about 52% by weight.
But RYHIX is far broader, holding 135 positions to 51 for FTXH, so beyond the top names it adds exposure FTXH doesn't have.
FTXH is cheaper at 0.6% vs 1.38% — a difference of $78 a year per $10,000 invested.
Over five years, FTXH returned +6.5% a year vs +5.1% for RYHIX.
Updated Nov 19, 2026
FTXH vs RYHIX side by side
| FTXH | RYHIX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | First Trust | Guggenheim |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.6% | 1.38% |
| Annual cost per $10k | $60 | $138 |
| 10-yr cost on $10k (prospectus) | — | $1,709 |
| Max front load | None | — |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +24.0% | +14.4% |
| 5-yr return (annualized) | +6.5% | +5.1% |
| 10-yr return (annualized) | — | +7.9% |
| Best quarter | +18.3% | +18.7% |
| Worst quarter | −17.4% | −14.4% |
| Net assets (fund) | $36.2M | $19.4M |
| Number of holdings | 51 | 135 |
| Portfolio turnover | 35% | 244% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FTXH | RYHIX | Difference |
|---|---|---|---|
| 2025 | +24.0% | +14.4% | +9.6% |
| 2024 | +3.0% | +0.6% | +2.4% |
| 2023 | −1.4% | +5.8% | −7.2% |
| 2022 | +2.5% | −11.6% | +14.1% |
| 2021 | +6.1% | +19.2% | −13.1% |
| 2020 | +10.9% | +18.9% | −8.1% |
| 2019 | +22.4% | +22.8% | −0.4% |
| 2018 | −8.4% | +1.6% | −9.9% |
| 2017 | +18.8% | +23.5% | −4.7% |
Source: Fund prospectus bar charts
Holdings overlap
11 of FTXH's top 25 holdings also appear in RYHIX's top 25.
| Holding | FTXH | RYHIX |
|---|---|---|
| Eli Lilly & Company | 7.77% | 3.63% |
| Abbvie Inc | 7.39% | 2.52% |
| Merck & Company Inc | 7.07% | 2.04% |
| Johnson & Johnson | 6.96% | 2.88% |
| Bristol-myers Squibb Company | 6.29% | 1.22% |
| Cardinal Health Inc | 3.53% | 0.86% |
| Vertex Pharmaceuticals Inc | 3.41% | 1.34% |
| Amgen Inc | 3.18% | 1.56% |
| Pfizer Inc | 2.97% | 1.25% |
| Gilead Sciences Inc | 2.89% | 1.39% |
| Regeneron Pharmaceuticals Inc | 2.72% | 0.90% |
Source: SEC Form N-PORT
FTXH top 10
- Eli Lilly & Company — 7.77%
- Abbvie Inc — 7.39%
- Merck & Company Inc — 7.07%
- Johnson & Johnson — 6.96%
- Bristol-myers Squibb Company — 6.29%
- Biogen Inc — 3.84%
- Viatris Inc — 3.62%
- Cardinal Health Inc — 3.53%
- Vertex Pharmaceuticals Inc — 3.41%
- Amgen Inc — 3.18%
RYHIX top 10
- Eli Lilly & Company — 3.63%
- Johnson & Johnson — 2.88%
- Abbvie Inc — 2.52%
- Unitedhealth Group Inc — 2.22%
- Merck & Company Inc — 2.04%
- Thermo Fisher Scientific Inc — 1.61%
- Amgen Inc — 1.56%
- Abbott Laboratories — 1.42%
- Gilead Sciences Inc — 1.39%
- Vertex Pharmaceuticals Inc — 1.34%
FAQ
What is the difference between FTXH and RYHIX?
Which is cheaper, FTXH or RYHIX?
Should I own both FTXH and RYHIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.